Trial Profile
Controlling glycaemic variables with pioglitazone prior to and during therapy with peginterferon alfa-2a + ribavirin does not improve early virological response in patients with chronic genotype 1 hepatitis C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2012
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C; Insulin resistance
- Focus Therapeutic Use
- Acronyms SENSITIZE
- 15 Feb 2012 Results published in the Hepatology.
- 08 Nov 2011 Results including 72 week data presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 04 Nov 2011 Primary endpoint 'Early-virological-response-rate' has not been met (3063700) as reported by result presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.